Recent events
Recent events tied to this brand in public sources.
Back to profile7 entries
2021
Genomenon and Alexion announce rare-disease genomics collaboration
Genomenon announced a collaboration with Alexion to produce genomic landscapes and make curated genetic datasets and information on therapies or clinical trials available to doctors, researchers, and clinicians through Genomenon's Mastermind Genomic Search Engine.
2021
AstraZeneca completes acquisition of Alexion
AstraZeneca completed its $39 billion acquisition of Alexion Pharmaceuticals, following regulatory clearances. The deal included cash and newly issued AstraZeneca shares for Alexion shareholders.
2021
Alexion highly commended in Treasury Today's Adam Smith Awards
Alexion Pharmaceuticals was highly commended for “Harnessing the Power of Technology” in Treasury Today's Adam Smith Awards. The article says the recognition took place last week but does not provide a calendar date.
2020
AstraZeneca announces plan to acquire Alexion
AstraZeneca announced plans to acquire Alexion for approximately $39 billion. The boards of both companies approved the acquisition, which was expected to close in the third quarter of 2021 subject to regulatory clearances and shareholder approval.
2020
Alexion raises 2020 revenue and earnings guidance
Alexion said it now expects fiscal 2020 non-GAAP earnings per share of $10.65 to $10.95 and total revenues of $5.55 billion to $5.60 billion, revising both ranges upward.
2019
FDA approves Ultomiris for atypical hemolytic uremic syndrome
The U.S. Food and Drug Administration approved Alexion Pharmaceuticals’ Ultomiris for use in treating atypical hemolytic uremic syndrome (aHUS), according to the company.
2019
FDA approves Ultomiris for atypical hemolytic uremic syndrome
The U.S. Food and Drug Administration approved Alexion Pharmaceuticals' Ultomiris for treating atypical hemolytic uremic syndrome (aHUS), its second rare blood disorder indication.